Multi-peptide vaccine with XS15 for adults with acute myeloid leukemia in remission

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1 interventional trial evaluating a peptide vaccine designed to stimulate an immune response against AML-associated targets. The vaccine uses a nine-peptide cocktail administered with the TLR1/2 ligand XS15 in Montanide adjuvant, given subcutaneously. Participants are adults with AML who have achieved CR or CRi after initial treatment, with MRD positivity allowed, and may be on or off maintenance therapy. Two vaccinations are planned within six weeks, with an optional booster if responses are insufficient, and the study will monitor safety, tolerability, immunogenicity, and early signs of efficacy. Enrollment is at University Hospital Tuebingen, led by the center's team in Germany.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or females aged ≥18 years of age
* Existence of a written informed consent
* Documented diagnosis of AML according to WHO guidelines

  * morphological complete remission (CR) or complete remission with incomplete blood count recovery (CRi)
  * positive MRD is permitted
  * completion of previous intensive therapy (first vaccination 4-28 weeks after last application of chemotherapy) or
  * ongoing low intensity treatment with e.g. hypomethylating agents (HMA), venetoclax, etc.
  * ongoing maintenance treatment with e.g. oral azacytidine or midostaurin is permitted.
  * not eligible for allogeneic stem cell transplantation
* Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
* Adequate organ function laboratory values.

  * bilirubin ≤ 3 times upper limit range (exception isolated indirect hyperbilirubinemia (Morbus Gilbert-Meulengracht)).
  * alanine aminotransferase (ALT) and aminotransferase (AST), ≤ 5 times upper limit range
  * creatinine clearance GFR \> 30 ml/min (CKD-EPI)
  * platelets \> 50.000/μl
  * absolute CD3+ T cell count ≥ 200/μl
* negative serological hepatitis B test or negative PCR in case of positive serological test without evidence of an active infection, negative testing of hepatitis C RNA, negative HIV test within 6 weeks prior to study inclusion
* Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one highly effective method) of contraception (for more detailed information see chapter 5.7 Contraception, pregnancy, sperm donation and nursing). This should be started from the signing of the informed consent and be continued until 3 months (both female and male patients) after last vaccination).
* For FCBP two negative pregnancy tests (sensitivity of at least 25 mlU/mL) prior to first application of first vaccination, one at screening and the other prior (\< 24 h) to first vaccination
* Postmenopausal or evidence of non-child-bearing status

Exclusion Criteria:

* Pregnant or breastfeeding.
* Unwilling or unable to follow the study schedule for any reason.
* Chemotherapy or other systemic therapy or radiotherapy, up to 14 days prior to the first dose of study drug (ongoing maintenance treatment or low intensity treatment is permitted).
* Concurrent or previous treatment within 28 days in another interventional clinical trial with an investigational anticancer therapy or any other investigational therapy, which would interfere with the study's primary and secondary endpoints.
* Major surgery within 28 days of dosing of study drug.
* Treatment with immunotherapy agents within 28 days of dosing of study drug.
* Diagnosis of acute promyelocytic leukemia (APL)
* Autoimmune disease that requires or has required treatment with systemic immunosuppressive treatments, except low dose corticosteroids (\< 10 mg/ day), in the past 1 year.
* Prior history of malignancies, other than AML/myelodysplastic syndrome (MDS), unless the subject has been free of the disease for

  ≥ 2 years. Exceptions include the following: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, histological finding of prostate cancer of TNM stage T1
* Prior stem cell allograft or organ transplantation
* Ongoing or active infection (including SARS-CoV-2)
* Have received any live vaccination within 28 days prior to the first dose of AML-VAC-XS15.

Where it's running

• University Hospital Tuebingen
  Tübingen, Baden-Wurttemberg, Germany Recruiting

Study contacts

• Study coordinator: Juliane Walz, Prof. Dr.
• Email: kketi@med.uni-tuebingen.de
• Phone: +49 7071 29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Venetoclax and Azacitidine with or without Quizartinib in older/unfit adults with AML

  This trial tests whether adding Quizartinib to Venetoclax and Azacitidine helps older or unfit adults with AML live longer compared with the standard Venetoclax and Azacitidine therapy.

  Recruiting at 24 sites Phase 3 PETHEMA Foundation · Santiago de Compostela, A Coruña and 51 other locations · NCT07478991

• Combining revumenib with azacitidine and venetoclax for treating specific types of acute myeloid leukemia

  This study is testing a new combination of medications to see if it can help people with specific types of acute myeloid leukemia who can't have intensive chemotherapy.

  Recruiting at 128 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · Los Angeles, California and 200 other locations · NCT06652438

• Comparing different drug combinations for newly diagnosed acute myeloid leukemia

  This study is testing different combinations of drugs to see which one works best for people with newly diagnosed acute myeloid leukemia who can't handle strong chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06532552

• Real-world outcomes for adults with AML treated with new drugs (BoxTrial)

  This project will follow adults with AML treated in routine care across Italy to see how new approved drugs and combinations perform over at least two years.

  Recruiting at 2 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · San Giovanni Rotondo and 1 other locations · NCT06513273

• Hydroxyurea plus valproic acid or 6‑mercaptopurine plus valproic acid for unfit adults with AML or high‑risk MDS

  This study will try two low‑toxicity oral drug combinations—hydroxyurea plus valproic acid, or 6‑mercaptopurine plus valproic acid—in adults with acute myeloid leukemia or high‑risk myelodysplastic syndrome who are not fit for standard chemotherapy.

  Recruiting Phase 1/2 Haukeland University Hospital · Bergen, Bergen · NCT06199557

• Evaluating ABD-3001 for patients with difficult-to-treat blood cancers

  This study is testing a new treatment called ABD-3001 to see if it can help adults with hard-to-treat blood cancers like Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes feel better and stay safe during the process.

  Recruiting at 3 sites Phase 1/2 Advanced BioDesign · Marseille, France and 2 other locations · NCT05601726

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.